Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Leaders Show United Front On COVID-19

Lilly CEO Warns Against Trump-Style Unilateralism

Executive Summary

Costs will be an issue, but not today; industry and healthcare systems are working at breakneck speed to catch up with the deadly virus.

You may also be interested in...



Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies

US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.

‘Agile’ Approach Aims To Accelerate Ridgeback’s COVID-19 Timeline

The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.

Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130096

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel